|
|
|
|
| LEADER |
03824nmm a2200373 u 4500 |
| 001 |
EB001419676 |
| 003 |
EBX01000000000000000911680 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
170502 ||| eng |
| 020 |
|
|
|a 9781441907172
|
| 100 |
1 |
|
|a Marshall, John L.
|e [editor]
|
| 245 |
0 |
0 |
|a Cancer Therapeutic Targets
|h Elektronische Ressource
|c edited by John L. Marshall
|
| 250 |
|
|
|a 1st ed. 2017
|
| 260 |
|
|
|a New York, NY
|b Springer New York
|c 2017, 2017
|
| 300 |
|
|
|a 51 illus., 42 illus. in color. eReference
|b online resource
|
| 505 |
0 |
|
|a AKT -- Anti-4-1BB/4-1BBL -- Anti-B7-H4 -- Anti-CD40/Anti CD40L -- Anti-Idiotype antibodies -- Anti-Programmed Death 1 (PD1) -- B7.1 -- Bacterial Vaccines -- Brachyury -- CCL21 -- CD4+ T Cells -- CD8 T Cells -- CEA -- CTLA-4 -- Dendritic cells -- DNA Vaccines -- EGFR, Immunology -- Fc Gamma R -- Gangliosides -- Glucocorticoid-Induced TNF Receptor (GITR) -- GM-CSF and Whole Cells -- gp100 -- HER2/neu -- indoleamine 2,3-dioxygenase -- Integrins, Immunology -- Interferon alpha -- Interleukin 2 -- Interleukin 7 -- Interleukin 12 -- Interleukin 15 -- Interleukin 21 -- Lymphocyte Activation Gene 3 (LAG-3) -- MART-1 -- MUC1 -- NK Cells -- P53, Immunology -- PAP -- Peptide Vaccine: Overview -- Proteins (Mesothelin) -- PSA -- Survivin -- Telomerase-related proteins -- TGF Beta Receptors -- TLR7 and TLR8, Resiquimod, and 852A -- TLR9 -- Transforming Growth Factor β -- Tregs -- Tyrosinase: Overview -- VEGF -- Viral-Like Proteins -- Whole-Cell Vaccines -- FGF-FGFR Signaling in Cancer -- MMPs -- PDGF -- TIE -- VEGF A -- VEGF Ligands -- AXL -- B-Raf -- CKIT -- DNA Repair, Overview -- EGFR, Growth factors -- HER3 -- IGF 1 and IGF 2 -- Jak2/Stat5a/b Pathway in Prostate Cancer -- JNK Signaling in Diseases -- K-Ras -- MET -- NEDD9 -- N-Ras -- P38 -- Rac 1 -- Type I Insulin-Like Growth Factor Receptor -- Anti-apoptotic Bcl-2 -- BH3-Only Mimetics -- Caspase -- DR4 and DR5 -- FLIP -- MLH1 -- NF-κB -- PARP -- ROS -- X-Linked IAP -- APC -- AR, Overview -- BRCA 1 and 2 -- Cell Cycle Related Kinases -- ER -- Histone Deacetylases (HDAC) -- Methylation -- PR -- Retinoids -- Topoisomerase 1 -- Topoisomerase 2 -- VDR.
|
| 653 |
|
|
|a Molecular Medicine
|
| 653 |
|
|
|a Molecular biology
|
| 653 |
|
|
|a Internal medicine
|
| 653 |
|
|
|a Cancer research
|
| 653 |
|
|
|a Oncology
|
| 653 |
|
|
|a Internal Medicine
|
| 653 |
|
|
|a Oncology
|
| 653 |
|
|
|a Pharmacology
|
| 653 |
|
|
|a Cancer Research
|
| 653 |
|
|
|a Laboratory Medicine
|
| 653 |
|
|
|a Laboratory medicine
|
| 653 |
|
|
|a Pharmacology/Toxicology
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b Springer
|a Springer eBooks 2005-
|
| 856 |
4 |
0 |
|u https://doi.org/10.1007/978-1-4419-0717-2?nosfx=y
|x Verlag
|3 Volltext
|
| 082 |
0 |
|
|a 614.5999
|
| 520 |
|
|
|a In the past decade, we have experienced an explosion of new information about cancer therapeutic targets. Many of the targets have been validated by the discovery and approval of new medicines which have been approved for the treatment of cancer. On the heels of these successes, innumerable new targets and new potential therapeutics are being developed by many different groups including government agencies, pharmaceutical companies, biotechnology companies, academic institutions, and individual investigators. Understanding the expanding "universe" of cancer therapies is therefore becoming impossible and no single source exists which serves as a reference for the involved parties. Further, the interested parties have vastly different areas of expertise, from focused laboratory based science, to clinical research, to corporate and regulatory oversight. The text would be updated every two years, more often depending on pace of change, interest and sales. While useful online, this reference book would likely be kept in hard copy as well
|